Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T14:11:37.453Z.
Calculation as of: 2026-10-06T14:11:37.453Z.
Quote observation: 2026-10-06T14:10:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3e31615b66e5acc6c2b7b3f8a521ec69124b31f47383f0f9627e8176a83f275d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$4.71B
PS Ratio
2473.57
TTM Avg
1806.21
3Y Avg
686.61
5Y Avg
531.46
Market Cap
$4.58B
PS Ratio
14.85
TTM Avg
10.54
3Y Avg
6.93
5Y Avg
8.46
Market Cap
$4.41B
PS Ratio
20.81
TTM Avg
15.09
3Y Avg
15.20
5Y Avg
15.20
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | $4.66B | N/A | N/A | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 2.96 | 2.20 | 2.14 | 2.77 |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.71B | 2473.57 | 1806.21 | 686.61 | 531.46 |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.82B | 7.79 | 9.96 | 8.15 | 13.53 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.58B | 14.85 | 10.54 | 6.93 | 8.46 |
| BillionToOne, Inc. (BLLN)vs › | $4.91B | 12.35 | 14.66 | 14.66 | 14.66 |
| Erasca, Inc. (ERAS)vs › | $4.93B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.42B | 3.32 | 3.55 | 2.38 | 2.56 |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.41B | 20.81 | 15.09 | 15.20 | 15.20 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.04B | N/A | 12.01 | 39.75 | 43.00 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
